SCHEMBL5916564

SCHEMBL5916564

O=c1c2cccc(O)c2[se]n1-c1cccnc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALOX12 P18054 2/20 0.42
▸ MAPT P10636 3/20 0.39
▸ HTT P42858 3/20 0.39
▸ METAP2 P50579 3/20 0.39
▸ ALDH1A1 P00352 2/20 0.39
▸ HSD17B10 Q99714 2/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ QSOX1 O00391 1/20 0.39
▸ RGS12 O14924 1/20 0.39
▸ PMM2 O15305 1/20 0.39
▸ PLIN1 O60240 1/20 0.39
▸ GMNN O75496 1/20 0.39
▸ BBOX1 O75936 1/20 0.39
▸ LMNA P02545 1/20 0.39
▸ TP53 P04637 1/20 0.39
▸ CYBB P04839 1/20 0.39
▸ BCHE P06276 1/20 0.39
▸ GLA P06280 1/20 0.39
▸ POLB P06746 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5916493 0.84 METAP2 (0.41) ALOX12MAPTHTTMETAP2ALDH1A1
SCHEMBL5916543 0.83 METAP2 (0.42) ALOX12MAPTHTTMETAP2ALDH1A1
SCHEMBL5916696 0.83 ALDH1A1 (0.40) ALOX12MAPTHTTMETAP2ALDH1A1
SCHEMBL5916612 0.82 METAP2 (0.57) ALOX12MAPTHTTMETAP2ALDH1A1
SCHEMBL5916664 0.78 HTT (0.43) ALOX12MAPTHTTMETAP2ALDH1A1
SCHEMBL5916907 0.77 METAP2 (0.68) ALOX12MAPTHTTMETAP2ALDH1A1
SCHEMBL5917044 0.75 METAP2 (0.45) ALOX12MAPTHTTMETAP2ALDH1A1
SCHEMBL5916619 0.74 ALDH1A1 (0.44) ALOX12MAPTHTTMETAP2ALDH1A1
SCHEMBL5916550 0.73 GAA (0.42) HTTMETAP2ALDH1A1KDM4EMEN1
SCHEMBL10027279 0.70 PI4KA (0.45) ALOX12MAPTHTTHSD17B10KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060135569-A1 Use of benzisoselenazolone compounds against ischemic myocardial damage INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2006-06-22 — — US claimed
EP-1541145-A1 THE USE OF BENZISOSELENAZOLONE COMPOUNDS AGAINST ISCHEMIC MYOCARDIAL DAMAGE Institute of Materia, Chinese Academy of Medical Sciences (CN) 2005-06-15 — — EP claimed
US-20060135569-A1 Use of benzisoselenazolone compounds against ischemic myocardial damage INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2006-06-22 — — US disclosed
EP-1541145-A1 THE USE OF BENZISOSELENAZOLONE COMPOUNDS AGAINST ISCHEMIC MYOCARDIAL DAMAGE Institute of Materia, Chinese Academy of Medical Sciences (CN) 2005-06-15 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060135569-A1 Use of benzisoselenazolone compounds against ischemic myocardial damage TNNI3, TNNT2, MYLK2 ALOX12 925/4885MAPT 4712/4885HTT 4854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback